Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46 results about "Macular Pigment" patented technology

Macular pigment is comprised of Zeaxanthin and Lutein, which are found in the center of the macula (fovea) at a natural 2:1 ratio. MPOD (Macular Pigment Optical Density) is important for three specific reasons:

Diagnostic, Prescriptive, and Data-Gathering System and Method For Macular Pigment Deficits and Other Eye Disorders

ActiveUS20100241450A1Compact and inexpensive and well-suited for placement and operationInexpensive and convenientDrug and medicationsNutrition controlPatient dataMedical prescription
A macular health measurement and storage system comprises a plurality of macular-pigment measurement machine for measuring macular pigment density in humans, a plurality of computers each of which is associated with a corresponding one the macular-pigment measuring machines, and a central host. The plurality of macular-pigment measurement machines include a device for receiving macular pigment data from a patient, at least one data transfer port, and at least one processor that enables the transfer of the macular pigment data from the transfer port. The plurality of computers include a first port coupled to the data transfer port of the corresponding macular-pigment measurement machine for receiving the macular pigment data. Each of the computers includes a second port for transferring patient data. The central host is coupled to the second ports on each of the plurality of computers. The central host includes a storage device for storing the patient data.
Owner:ZEAVISION LLC

Identifying Subjects in Need of Treatment

A method of identifying a human subject, more likely than a subject selected at random from the general population, to have one or more of the following: (i) a low macular pigment concentration in the eye or eyes; (ii) a low visual performance, or (iii) an atypical “central dip” macular pigment distribution; the method comprising the steps of: measuring at least one cognitive function of the subject; comparing the measured cognitive function with a pre-determined threshold; and, if the measured cognitive function is below the threshold, declaring the subject as being more likely to have one or more of low macular pigment concentration in the eye or eyes, low visual performance or an atypical ‘central dip’ macular pigment profile.
Owner:HOWARD FOUND HLDG

Composition For Improving Macular Pigment Density And Preventing Or Treating Age-Related Macular Degeneration

The present invention provides a composition for improving macular pigment optical density and preventing or treating age-related macular optical degeneration. The composition comprises lutein, zeaxanthin and tea extracts, wherein the weight ratio of zeaxanthin to lutein is more than or equal to 1. The composition may prevent formation of choroidal neovascularization to achieve effects on comprehensively preventing or treating age-related macular optical degeneration (AMD).
Owner:ZHEJIANG MEDICINE CO LTD XINCHANG PHAMACEUTICAL FACTORY

Arrangement and method for determining the two-dimensional distribution of fundus pigments, particularly of the macular pigment xanthophyll

An arrangement and method for determining the two-dimensional distribution of fundus pigments, particularly of the xanthophyll macular pigment. The arrangement for carrying out the method comprises an illumination unit which illuminates the retina via an illumination beam path directed to the ocular fundus, observation optics located in the observation beam path proceeding from the ocular fundus, an image processing unit, elements for beam deflection and a central controlling and evaluating unit. In the method, a two-dimensional reflection image of the retina is recorded in a selected narrow-band wavelength region. In evaluating this two-dimensional reflection image, site-specific areas are established for determining the optical density and comparison values. The optical density of the fundus pigment at every fundus location is calculated from the negative logarithmic value of the quotient of the intensity value of the reflection image IR(λ) at this fundus site to a comparison intensity value of the reflection image IR(λ)Comparison. The suggested solution for the objective detection of the two-dimensional distribution of the optical density of the macular pigment xanthophyll is also suitable in principle for determining the distribution of other fundus pigments.
Owner:CARL ZEISS MEDITEC AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products